Document Detail


NBI-5788, an altered MBP83-99 peptide, induces a T-helper 2-like immune response in multiple sclerosis patients.
MedLine Citation:
PMID:  11079539     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We assessed the immune response induced in multiple sclerosis (MS) patients who had received NBI-5788, an altered peptide ligand (APL) designed from an immunodominant region (83-99) of the neuroantigen myelin basic protein (MBP) (5, 10, or 20 mg subcutaneously weekly for 4 weeks). The mean frequency of NBI-5788-responsive T cells (stimulation index > 3) in MS patients treated with the APL was 35.8 +/- 12.8% (n = 7) compared with a mean frequency of 6.2 +/- 1.3% (n = 7) for the untreated patients. The mean frequency of whole MBP-responsive T cells in MS patients treated with the APL was not significantly different from that of untreated patients (16.4 +/- 5.7% vs 18.0 +/- 6.3%, respectively). NBI-5788-reactive T-cell lines generated from NBI-5788-treated patients exhibited an increased frequency of cross-reactivity with MBP peptide 83-99 compared with NBI-5788-reactive lines from control MS patients. Cytokine secretion by APL-reactive T-cell lines from NBI-5788-treated MS patients was more frequently T-helper 2-like compared with T-cell lines from untreated MS patients. These results demonstrate that subcutaneous administration of a soluble APL based on the MBP peptide 83-99 in MS patients can induce an APL-reactive immune response in which T lymphocytes cross-reactive with the immunodominant neuroantigen MBP secrete anti-inflammatory cytokines. The significant heterogeneity in immune response between individuals indicates the need for clinical laboratory correlation during the course of therapeutic trials.
Authors:
P D Crowe; Y Qin; P J Conlon; J P Antel
Related Documents :
16477479 - Neuropsychology of multiple sclerosis--an overview.
1839869 - An intraoral prosthesis to control drooling in a patient with amyotrophic lateral scler...
18677639 - Employment in multiple sclerosis. exiting and re-entering the work force.
3587739 - Modulation of the long-latency reflex to stretch by the supplementary motor area in hum...
20351669 - Use of neck magnetic resonance venography, doppler sonography and selective venography ...
7629529 - Diagnostic value of paraclinical tests in multiple sclerosis: relative sensitivities an...
20092879 - Overactive bladder is not only overactive but also hypersensitive.
16269419 - Prognostic differences between different types of bundle branch block during the early ...
23632359 - Decompensated cirrhotics have slower intestinal transit times as compared with compensa...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Annals of neurology     Volume:  48     ISSN:  0364-5134     ISO Abbreviation:  Ann. Neurol.     Publication Date:  2000 Nov 
Date Detail:
Created Date:  2000-11-15     Completed Date:  2000-12-14     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7707449     Medline TA:  Ann Neurol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  758-65     Citation Subset:  IM    
Affiliation:
Neurocrine Biosciences, San Diego, CA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antibody Specificity / immunology
Cytokines / drug effects,  immunology*
Female
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Multiple Sclerosis / drug therapy*,  immunology*,  pathology
Myelin Basic Proteins / administration & dosage*,  drug effects,  immunology
Peptide Fragments / administration & dosage*,  pharmacology*
T-Lymphocytes, Helper-Inducer / drug effects*,  immunology*
Chemical
Reg. No./Substance:
0/Cytokines; 0/Myelin Basic Proteins; 0/NBI 5788; 0/Peptide Fragments

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Multi-minicore disease--searching for boundaries: phenotype analysis of 38 cases.
Next Document:  Mitochondrial complex I deficiency in the epileptic focus of patients with temporal lobe epilepsy.